in this issue
Regions :: North America :: U.S.
Mallinckrodt to acquire Cadence Pharmaceuticals
10:44 AM MST | February 13, 2014 | Natasha Alperowicz
Mallinckrodt, a specialty pharmaceutical and medical imaging group, says that it has entered into a definitive agreement to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00/share in cash, or approximately $1.3 billion. Subject to terms and conditions, the parties expect the transaction to close in mid- to late March. Mallinckrodt says it expects the acquisition to be immediately accretive to its fiscal 2014 adjusted diluted earnings per share and significantly accretive to its fiscal 2015 adjusted diluted earnings per share. Cadence is...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee